Clinical trials: Alzheimer’s disease

ELND005-AG201:  A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND002 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease.
  • Indication:  Patients with moderate to severe Alzheimer's disease with clinically significant agitation and aggression
  • Purpose:  Determine if ELND005 reduces symptoms of agitation and aggression after 12 weeks of treatment compared to placebo.

Principal Investigator:  Michael Mega, M.D., Ph.D.
Sponsor:  ELAN
For more information, please contact Crystal Turner, CCRP at 503 216-1017